PE20040948A1 - METHOD OF TREATMENT WITH NELFINAVIR - Google Patents
METHOD OF TREATMENT WITH NELFINAVIRInfo
- Publication number
- PE20040948A1 PE20040948A1 PE2004000146A PE2004000146A PE20040948A1 PE 20040948 A1 PE20040948 A1 PE 20040948A1 PE 2004000146 A PE2004000146 A PE 2004000146A PE 2004000146 A PE2004000146 A PE 2004000146A PE 20040948 A1 PE20040948 A1 PE 20040948A1
- Authority
- PE
- Peru
- Prior art keywords
- nelfinavir
- fat
- once
- refers
- pharmaceutical composition
- Prior art date
Links
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 title abstract 5
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 title abstract 5
- 229960000884 nelfinavir Drugs 0.000 title abstract 5
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN METODO PARA TRATAR EL VIRUS DE INMUNODEFICIENCIA HUMANA (HIV) QUE COMPRENDE ADMINISTRAR NELFINAVIR, O SUS ESTEREOISOMEROS, SOLVATOS, SALES O PROFARMACOS, CONTENIDO EN UNA COMPOSICION FARMACEUTICA AL MENOS UNA VEZ AL DIA DURANTE AL MENOS DOS SEMANAS CONJUNTAMENTE CON ALIMENTOS QUE CONTIENEN MAS DE 800 KCAL Y MAS DE 40% DE GRASA POR CONTENIDO ENERGETICO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE NELFINAVIR Y GRASA EN UNA RELACION EN PESO DE AL MENOS 25:1 DE GRASA Y NELFINAVIR. ESTE METODO PERMITE UNA MEJOR BIODISPONIBILIDAD DEL NELFINAVIRREFERS TO A METHOD TO TREAT THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) THAT INCLUDES ADMINISTERING NELFINAVIR, OR ITS STEREOISOMERS, SOLVATES, SALTS OR PRO-DRUGS, CONTAINED IN A PHARMACEUTICAL COMPOSITION AT LEAST ONCE ONCE AT LEAST ONCE A DAY. THEY CONTAIN MORE THAN 800 KCAL AND MORE THAN 40% OF FAT BY ENERGY CONTENT. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING NELFINAVIR AND FAT IN A WEIGHT RATIO OF AT LEAST 25: 1 OF FAT AND NELFINAVIR. THIS METHOD ALLOWS A BETTER BIOAVAILABILITY OF NELFINAVIR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44644403P | 2003-02-10 | 2003-02-10 | |
| US52425803P | 2003-11-21 | 2003-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040948A1 true PE20040948A1 (en) | 2004-12-27 |
Family
ID=32853430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000146A PE20040948A1 (en) | 2003-02-10 | 2004-02-09 | METHOD OF TREATMENT WITH NELFINAVIR |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1605942A1 (en) |
| JP (1) | JP2006517221A (en) |
| AR (1) | AR043133A1 (en) |
| BR (1) | BRPI0407174A (en) |
| CA (1) | CA2515095A1 (en) |
| CL (1) | CL2004000202A1 (en) |
| MX (1) | MXPA05008425A (en) |
| NL (1) | NL1025449C2 (en) |
| PA (1) | PA8595301A1 (en) |
| PE (1) | PE20040948A1 (en) |
| TW (1) | TW200423922A (en) |
| UY (1) | UY28183A1 (en) |
| WO (1) | WO2004069251A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
-
2004
- 2004-01-29 WO PCT/IB2004/000313 patent/WO2004069251A1/en not_active Application Discontinuation
- 2004-01-29 BR BR0407174-3A patent/BRPI0407174A/en not_active IP Right Cessation
- 2004-01-29 CA CA002515095A patent/CA2515095A1/en not_active Abandoned
- 2004-01-29 JP JP2006502411A patent/JP2006517221A/en active Pending
- 2004-01-29 EP EP04706250A patent/EP1605942A1/en not_active Withdrawn
- 2004-01-29 MX MXPA05008425A patent/MXPA05008425A/en unknown
- 2004-02-05 CL CL200400202A patent/CL2004000202A1/en unknown
- 2004-02-09 PA PA20048595301A patent/PA8595301A1/en unknown
- 2004-02-09 AR ARP040100399A patent/AR043133A1/en unknown
- 2004-02-09 PE PE2004000146A patent/PE20040948A1/en not_active Application Discontinuation
- 2004-02-09 TW TW093102921A patent/TW200423922A/en unknown
- 2004-02-10 UY UY28183A patent/UY28183A1/en not_active Application Discontinuation
- 2004-02-10 NL NL1025449A patent/NL1025449C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2004000202A1 (en) | 2005-03-18 |
| JP2006517221A (en) | 2006-07-20 |
| EP1605942A1 (en) | 2005-12-21 |
| NL1025449C2 (en) | 2005-03-15 |
| UY28183A1 (en) | 2004-09-30 |
| CA2515095A1 (en) | 2004-08-19 |
| NL1025449A1 (en) | 2004-08-12 |
| PA8595301A1 (en) | 2005-08-04 |
| AR043133A1 (en) | 2005-07-20 |
| TW200423922A (en) | 2004-11-16 |
| BRPI0407174A (en) | 2006-02-07 |
| WO2004069251A1 (en) | 2004-08-19 |
| MXPA05008425A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088329A (en) | NEW DIAZAESPIROALCANOS AND ITS USE FOR THE TREATMENT OF DISEASES MEDIATED BY CCR8 | |
| NO20071505L (en) | Method of Composition of Drug Delivery Devices. | |
| BRPI0415639A (en) | once daily controlled release oxycodone oral dosage forms | |
| CO2021006482A2 (en) | Cyclic ureas | |
| DOP2011000264A (en) | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY | |
| ATE410424T1 (en) | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | |
| UY28945A1 (en) | PIRROLOPIRIDINE DERIVATIVES | |
| DE602005007188D1 (en) | SUGAR LACTON CONTAINING HAIR TREATMENT COMPOSITION | |
| EA201992782A1 (en) | SUBSTITUTED INDOLINE DERIVATIVES AS MONEY VIRUS REPLICATION INHIBITORS | |
| CL2021003280A1 (en) | Methods of treating Fabry disease in patients who have renal failure | |
| RU2017120184A (en) | DRUGS TO DELAY THE COURSE OF PARKINSON'S DISEASE | |
| CL2020000491A1 (en) | Methods to increase and / or stabilize cardiac function in patients with Fabry disease. | |
| CL2021001388A1 (en) | Useful compounds in hiv therapy | |
| ATE468849T1 (en) | IDEBENONE FOR THE TREATMENT OF MUSCLE DYSTROPHIES | |
| NZ745184A (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| CY1115955T1 (en) | A STRONG PHARMACEUTICAL FORM | |
| UY26895A1 (en) | PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2 | |
| DE60019947D1 (en) | PREVENTION OF COLORECTAL CANCER | |
| PE20040948A1 (en) | METHOD OF TREATMENT WITH NELFINAVIR | |
| ECSP055673A (en) | DERIVATIVES OF 4- (3,5-DICIANOPHENOXI) PIRAZOL FOR USE AS REVERSE TRANSCRIPTASE MODULATORS IN HIV TREATMENT | |
| BRPI0519006A2 (en) | use of a fbpase inhibitor, kit of a pharmaceutical composition, use of a biguanide preparation and a fbpase inhibitor, therapeutic agent for diabetes mellitus, and combination of therapeutic agents | |
| AR111803A1 (en) | DERIVED FROM CICLOPENTAN [G] QUINAZOLIN-4-ONA AND ITS EMPLOYMENT IN THE TREATMENT OF CANCER RESISTANT TO PLATINUM | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| CL2022001079A1 (en) | Methods and compositions for the treatment of rett syndrome | |
| RU2015105452A (en) | DRUG FOR TREATMENT OF BONE NOSES, HEADACHES AND PAINS IN THE HEART |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |